Our portfolio of targeted and immuno-oncology therapies is focused on novel biological pathways that have potential to deliver breakthrough treatments for cancers with few options

FPA157 is an anti-CCR8 antibody engineered to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) to preferentially eliminate CCR8+ T regulatory (Treg) cells in the tumor microenvironment. Tregs inhibit anti-tumoral immune responses and act through multiple suppressive mechanisms. FPA157 is part of the Five Prime immuno-oncology antibody pipeline and is currently advancing through IND-enabling studies. The company expects to submit an IND for this program in the first half of 2022.

Preclinical data shared in a Late Breaker poster presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) support evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors.

Key highlights from the SITC2020 poster include:

  • CCR8 expression is highly restricted to T regulatory (Treg) cells within the tumor
  • Preclinical efficacy studies demonstrate that anti-CCR8 antibody treatment depletes CCR8+ Tregs in the tumor microenvironment while sparing peripheral Treg subsets
  • Anti-CCR8 treatment elicits the development of robust anti-tumor memory responses
  • FPA157 leads to potent natural killer (NK) cell-dependent killing of CCR8+ target cells